Latest Breaking News On - Elaine 1 trial - Page 1 : comparemela.com

Jane Lowe Meisel, MD, discusses previously reported data from the ELAINE-1 and ELAINE-2 trials, their significance within the ESR1-mutant, ER-positive, HER2-negative breast cancer treatment paradigm, and the purpose of the ongoing ELAINE-3 trial.

Emory university school of medicineUnited statesJane lowe meiselDepartment of hematologySermonix pharmaceuticals incSermonix pharmaceuticalsDepartment of gynecologyMedical oncologyEmory university schoolPatients with esr1 mutantApr positiveHer2 negative breast cancerElaine 1 trialElaine 2 trialElaine 3 study